Moderna/$MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
5,800
ISIN
US60770K1079
Website
Moderna Metrics
BasicAdvanced
$13B
-
-$8.73
1.85
-
Price and volume
Market cap
$13B
Beta
1.85
52-week high
$129.39
52-week low
$23.15
Average daily volume
11M
Financial strength
Current ratio
4.218
Quick ratio
3.916
Long term debt to equity
6.974
Total debt to equity
7.401
Interest coverage (TTM)
-196.26%
Profitability
EBITDA (TTM)
-3,537
Gross margin (TTM)
-82.37%
Net profit margin (TTM)
-105.67%
Operating margin (TTM)
-117.37%
Effective tax rate (TTM)
1.44%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-15.84%
Return on equity (TTM)
-29.34%
Valuation
Price to revenue (TTM)
3.974
Price to book
1.26
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
-3.129
Free cash flow yield (TTM)
-31.95%
Free cash flow per share (TTM)
-1,047.79%
Growth
Revenue change (TTM)
-38.35%
Earnings per share change (TTM)
-44.29%
3-year revenue growth (CAGR)
-48.00%
3-year earnings per share growth (CAGR)
-36.46%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Bulls say / Bears say
Moderna's mRNA-4157, in combination with Merck's Keytruda, has shown promising results in early-stage trials for melanoma and head and neck squamous cell carcinoma, advancing to Phase III trials with potential accelerated approval pathways. (Investing.com)
The company has announced plans to cut costs by $1.4-1.7 billion by 2027, aiming to reach breakeven by 2028, demonstrating a commitment to improving its financial position. (Investing.com)
Moderna's acquisition of Japanese biotech OriCiro Genomics for $85 million is expected to enhance its mRNA synthesis process, reducing the time from design to product readiness. (Fintech Insight)
Moderna reported a larger-than-expected quarterly loss of $2.91 per share, attributed to a $238 million non-cash charge from terminating an agreement with a contract manufacturer. (Reuters)
The company faces intensifying competition in the RSV vaccine market from established players like GlaxoSmithKline and Pfizer, who have existing contracts and the ability to bundle RSV vaccines with other products. (Investing.com)
Moderna's path to profitability has been extended, with breakeven now projected for 2028, reflecting ongoing investments in research and development. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
Benzinga·14 hours ago
Moderna gets full US approval for COVID vaccine in children 6 months and older
Reuters·20 hours ago
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
Accesswire·21 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $13B as of July 11, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of July 11, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.